易方达沪深300医药ETF(512010)财务指标
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 本期已实现收益 |
-566,233,641.30 |
-2,575,654,499.21 |
-1,421,086,552.57 |
-1,644,661,628.85 |
| 本期利润 |
600,673,225.21 |
-2,644,052,814.77 |
-4,259,220,715.81 |
-2,739,620,401.33 |
| 加权平均基金份额本期利润 |
0.01 |
-0.05 |
-0.09 |
-0.07 |
| 本期加权平均净值利润率(%) |
2.73 |
-13.93 |
-23.80 |
-15.12 |
| 本期基金份额净值增长率(%) |
2.19 |
-12.44 |
-20.70 |
-13.88 |
| 期末可供分配利润 |
6,614,871,207.05 |
7,079,683,457.40 |
3,997,578,431.09 |
8,018,650,176.38 |
| 期末可供分配基金份额利润 |
0.12 |
0.11 |
0.08 |
0.16 |
| 期末基金资产净值 |
20,601,294,942.09 |
23,121,607,193.90 |
17,097,002,173.73 |
20,432,573,943.82 |
| 期末基金份额净值 |
0.37 |
0.36 |
0.33 |
0.41 |
| 基金份额累计净值增长率(%) |
47.28 |
44.12 |
30.52 |
64.60 |
微信公众号
证券之星APP
基本资料
